Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Acorda Therapeutics clinical trials
The registry lists 53 studies whose lead sponsor is Acorda Therapeutics or one of 3 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 23, 2021.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Acorda Therapeutics.
- Acorda Therapeutics38 studiesSame company
Something wrong?
- Biotie Therapies Inc.10 studies →Acquired — became part of Acorda Therapeutics, Apr 11, 2016 · source ↗
Something wrong?
- Biotie Therapies Corp.3 studies →Acquired — became part of Acorda Therapeutics, Apr 11, 2016 · source ↗
Something wrong?
- 2 studies →
Focus areas
Conditions Acorda Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 53. Browse all 53 →
- A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG TrialCompletedNCT01839279Phase 2
- Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord InjuryCompletedNCT00041717Phase 3
- Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesCompletedNCT02242487Phase 3
- Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)CompletedNCT03887884Phase 1
- Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesCompletedNCT02240030Phase 3
- Randomized Safety Study of CVT-301 Compared to an Observational Control GroupCompletedNCT02352363Phase 3
- Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.TerminatedNCT03051607Phase 3
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted after Biotie Therapies Inc. became part of Acorda Therapeutics
- SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)CompletedNCT02258152Phase 2
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsTerminatedNCT02453386Phase 3
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)CompletedNCT00595231Phase 2
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.TerminatedNCT02422940Phase 3
- Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing OffCompletedNCT01283594Phase 2/3
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- AC105 in Patients With Acute Traumatic Spinal Cord InjuryTerminatedNCT01750684Phase 2
- Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)TerminatedNCT02474407Phase 2
- Study of Oral Fampridine-SR in Multiple SclerosisCompletedNCT00127530Phase 3
- An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a RelapseCompletedNCT02398461Phase 1
- Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent VolunteersCompletedNCT00656357Phase 1/2
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug UsersTerminatedNCT03200080Phase 1
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted after Biotie Therapies Inc. became part of Acorda Therapeutics
- Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF EpisodesCompletedNCT01777555Phase 2
- An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.TerminatedNCT02316847Phase 2
- A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.CompletedNCT02271217Phase 3
- A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation PowderCompletedNCT02905227Phase 1
- Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of TozadenantTerminatedNCT03212313Phase 1
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted after Biotie Therapies Inc. became part of Acorda Therapeutics
- Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord InjuryCompletedNCT01683838Phase 3
- Study to Evaluate SYN115 in Parkinson's DiseaseCompletedNCT00605553Phase 2
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled TozadenantCompletedNCT02240290Phase 1
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" EpisodesCompletedNCT01617135Phase 2
- A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure EpisodeCompletedNCT01417078Phase 2
- A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)CompletedNCT02807675Phase 1
- A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) TabletsCompletedNCT02812394Phase 1
- A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking AdultsCompletedNCT02633839Phase 1
- A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart FailureCompletedNCT01944683Phase 1
- A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult VolunteersCompletedNCT02663999Phase 1
- A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With AsthmaCompletedNCT02633007Phase 1
- Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy AdultsCompletedNCT02609945Phase 1
- Study of Fampridine-SR Tablets in Multiple Sclerosis PatientsCompletedNCT00483652Phase 3
- A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic StrokeCompletedNCT01605825Phase 2
- An Intravenous Infusion Study of rHIgM22 in Patients With Multiple SclerosisCompletedNCT01803867Phase 1
- Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart FailureCompletedNCT01258387Phase 1
- Safety and Tolerability of Dalfampridine in Subjects With Cerebral PalsyCompletedNCT01468350Phase 1
- An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)CompletedNCT01535664
- Study of Fampridine-ER Tablets in Patients With Multiple SclerosisCompletedNCT01328379Phase 3
- Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral PalsyTerminatedNCT01405950Phase 1
- Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal ImpairmentCompletedNCT01316055Phase 1
- Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00654927Phase 3
- Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 TrialCompletedNCT00649792Phase 3
- Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 TrialCompletedNCT00648908Phase 3
- BTT-1023 in Rheumatoid ArthritisCompletedNCT00851240Phase 1
Sponsor listed in the registry: Biotie Therapies Corp. · First submitted before Biotie Therapies Corp. became part of Acorda Therapeutics
- Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00053417Phase 2
- Safety and Pharmacokinetics of ELB353 in Healthy MenCompletedNCT00977886Phase 1
Sponsor listed in the registry: Biotie Therapies Corp. · First submitted before Biotie Therapies Corp. became part of Acorda Therapeutics